Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology

Pei Ning Wang, Kun Ju Lin, Huei Chun Liu, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Shieh Yueh Yang*


研究成果: 雜誌貢獻期刊論文同行評審

10 引文 斯高帕斯(Scopus)


Introduction: Pyroglutamate-modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting AβpE3-40. Methods: Immunomagnetic reduction was used for quantification of AβpE3-40 in plasma from 46 participants. The concentrations of AβpE3-40 of these subjects were compared with 18F-florbetapir positron emission tomography (PET) images. Results: AβpE3-40 concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; P <.05). The cutoff value of AβpE3-40 for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of AβpE3-40 showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio. Discussion: We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using AβpE3-40 for screening pre-clinical subjects. Conclusion: These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.

期刊Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
出版狀態已發佈 - 2020

ASJC Scopus subject areas

  • 神經病學(臨床)
  • 精神病學和心理健康


深入研究「Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology」主題。共同形成了獨特的指紋。